Clinical Trial Update: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1 [Phase 2]

View source ↗

Summary

Phase 2 study of Inati-cel (Inaticabtagene Autoleucel) for newly diagnosed B-cell acute lymphoblastic leukemia in CR1 is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Inati-cel (Inaticabtagene Autoleucel)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Acute Lymphoblastic Leukemia, B Cell ALL | Phase 2 | Status: NOT_YET_RECRUITING